Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 2
2017 2
2018 2
2021 7
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
Okikiolu J, Woodley C, Cadman-Davies L, O'Sullivan J, Radia D, Garcia NC, Harrington P, Kordasti S, Asirvatham S, Sriskandarajah P, Saunders J, Saha C, Sanchez I, deLavallade H, McLornan DP, Harrison CN. Okikiolu J, et al. Among authors: saunders j. Leuk Res Rep. 2022 Dec 16;19:100360. doi: 10.1016/j.lrr.2022.100360. eCollection 2023. Leuk Res Rep. 2022. PMID: 36590864 Free PMC article.
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Mwesigwa B, Houser KV, Hofstetter AR, Ortega-Villa AM, Naluyima P, Kiweewa F, Nakabuye I, Yamshchikov GV, Andrews C, O'Callahan M, Strom L, Schech S, Anne Eller L, Sondergaard EL, Scott PT, Amare MF, Modjarrad K, Wamala A, Tindikahwa A, Musingye E, Nanyondo J, Gaudinski MR, Gordon IJ, Holman LA, Saunders JG, Costner PJM, Mendoza FH, Happe M, Morgan P, Plummer SH, Hickman SP, Vazquez S, Murray T, Cordon J, Dulan CNM, Hunegnaw R, Basappa M, Padilla M, Gajjala SR, Swanson PA 2nd, Lin BC, Coates EE, Gall JG, McDermott AB, Koup RA, Mascola JR, Ploquin A, Sullivan NJ, Kibuuka H, Ake JA, Ledgerwood JE; RV 508 Study Team. Mwesigwa B, et al. Among authors: saunders jg. Lancet Infect Dis. 2023 Dec;23(12):1408-1417. doi: 10.1016/S1473-3099(23)00344-4. Epub 2023 Aug 3. Lancet Infect Dis. 2023. PMID: 37544326 Clinical Trial.
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
Harrington P, Dillon R, Radia D, McLornan D, Woodley C, Asirvatham S, Raj K, Curto-Garcia N, Saunders J, Kordasti S, Harrison C, de Lavallade H. Harrington P, et al. Among authors: saunders j. Br J Haematol. 2022 Sep;198(6):1011-1015. doi: 10.1111/bjh.18302. Epub 2022 Jul 8. Br J Haematol. 2022. PMID: 35802024 Free PMC article.
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Harrington P, Doores KJ, Saunders J, de Lord M, Saha C, Lechmere T, Khan H, Lam HPJ, Reilly AO, Woodley C, Asirvatham S, Dillon R, Curto-Garcia N, Sullivan JO, Kordasti S, Raj K, Malim MH, Radia D, McLornan D, Harrison C, de Lavallade H. Harrington P, et al. Among authors: saunders j. Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3. Blood Cancer J. 2022. PMID: 35459222 Free PMC article. No abstract available.
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.
Harrington P, Kurshan A, Delord M, Lechmere T, Sheikh A, Saunders J, Saha C, Dillon R, Woodley C, Asirvatham S, Curto-Garcia N, Sullivan JO, Kordasti S, Radia D, McLornan D, Malim MH, Harrison C, Doores KJ, de Lavallade H. Harrington P, et al. Among authors: saunders j. Blood Adv. 2023 May 23;7(10):1954-1957. doi: 10.1182/bloodadvances.2022008375. Blood Adv. 2023. PMID: 36083126 Free PMC article. No abstract available.
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Harrington P, Doores KJ, Saha C, Saunders J, Child F, Dillon R, Saglam S, Raj K, McLornan D, Avenoso D, Kordasti S, O'Reilly A, Espehana A, Lechmere T, Khan H, Malim MH, Harrison C, Mehra V, de Lavallade H. Harrington P, et al. Among authors: saunders j. Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 2021 Oct 12. Cancer Cell. 2021. PMID: 34717827 Free PMC article. No abstract available.
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.
Harrington P, de Lavallade H, Doores KJ, O'Reilly A, Seow J, Graham C, Lechmere T, Radia D, Dillon R, Shanmugharaj Y, Espehana A, Woodley C, Saunders J, Curto-Garcia N, O'Sullivan J, Raj K, Kordasti S, Malim MH, Harrison CN, McLornan DP. Harrington P, et al. Among authors: saunders j. Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22. Leukemia. 2021. PMID: 34023850 Free PMC article. No abstract available.
Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021.
Saunders J, Curto-Garcia N, Sriskandarajah P, O'Sullivan J, Woodley C, Asirvatham S, Campbell-Drew M, Mathias J, Ellis T, Baker N, Radia DH, Ali S, Kordasti S, Harrington P, de Lavallade H, McLornan DP, Harrison CN. Saunders J, et al. Hemasphere. 2021 Jun 23;5(7):e609. doi: 10.1097/HS9.0000000000000609. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34179698 Free PMC article.
21 results